This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yao, J. C. Articles by Evans, D. B. Search for Related Content PubMed PubMed Citation Articles by Yao, J. C. Articles by Evans, D. B. Related Articles Related Correspondence Social Bookmarking                            What's this?

One Hundred Years After "Carcinoid": Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

James C. Yao, Manal Hassan, Alexandria Phan, Cecile Dagohoy, Colleen Leary, Jeannette E. Mares, Eddie K. Abdalla, Jason B. Fleming, Jean-Nicolas Vauthey, Asif Rashid, Douglas B. Evans

From the Departments of Gastrointestinal Medical Oncology, Surgical Oncology, and Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Corresponding author: James C. Yao, MD, Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; e-mail: jyao{at}mdanderson.org

Purpose Neuroendocrine tumors (NETs) are considered rare tumors and can produce a variety of hormones. In this study, we examined the epidemiology of and prognostic factors for NETs, because a thorough examination of neither had previously been performed.

Methods The Surveillance, Epidemiology, and End Results (SEER) Program registries were searched to identify NET cases from 1973 to 2004. Associated population data were used for incidence and prevalence analyses.

Results We identified 35,618 patients with NETs. We observed a significant increase in the reported annual age-adjusted incidence of NETs from 1973 (1.09/100,000) to 2004 (5.25/100,000). Using the SEER 9 registry data, we estimated the 29-year limited-duration prevalence of NETs on January 1, 2004, to be 9,263. Also, the estimated 29-year limited-duration prevalence in the United States on that date was 103,312 cases (35/100,000). The most common primary tumor site varied by race, with the lung being the most common in white patients, and the rectum being the most common in Asian/Pacific Islander, American Indian/Alaskan Native, and African American patients. Additionally, survival duration varied by histologic grade. In multivariate analysis of patients with well-differentiated to moderately differentiated NETs, disease stage, primary tumor site, histologic grade, sex, race, age, and year of diagnosis were predictors of outcome (P < .001).

Conclusion We observed increased reported incidence of NETs and increased survival durations over time, suggesting that NETs are more prevalent than previously reported. Clinicians need to be become familiar with the natural history and patterns of disease progression, which are characteristic of these tumors.

Supported in part by Dr. Raymond Sackler and the Parker family.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Tumor Biology and Prognosis of Gastrointestinal Carcinoids
  Hans Scherübl
  JCO 2008 26: 6012-6013 [Full Text]

This article has been cited by other articles:

				R. Garcia-Carbonero, J. Capdevila, G. Crespo-Herrero, J. A. Diaz-Perez, M. P. Martinez del Prado, V. Alonso Orduna, I. Sevilla-Garcia, C. Villabona-Artero, A. Beguiristain-Gomez, M. Llanos-Munoz, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE) Ann. Onc., February 5, 2010; (2010) mdq022v1. [Abstract] [Full Text] [PDF]

				C. Hantel, F. Lewrick, S. Schneider, O. Zwermann, A. Perren, M. Reincke, R. Suss, and F. Beuschlein Anti Insulin-Like Growth Factor I Receptor Immunoliposomes: A Single Formulation Combining Two Anticancer Treatments with Enhanced Therapeutic Efficiency J. Clin. Endocrinol. Metab., February 1, 2010; 95(2): 943 - 952. [Abstract] [Full Text] [PDF]

				B. Basu, B. Sirohi, and P. Corrie Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin Endocr. Relat. Cancer, January 29, 2010; 17(1): R75 - R90. [Abstract] [Full Text] [PDF]

				J. C. Yao, C. Lombard-Bohas, E. Baudin, L. K. Kvols, P. Rougier, P. Ruszniewski, S. Hoosen, J. St. Peter, T. Haas, D. Lebwohl, et al. Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial J. Clin. Oncol., January 1, 2010; 28(1): 69 - 76. [Abstract] [Full Text] [PDF]

				H. Minn, S. Kauhanen, M. Seppanen, and P. Nuutila 18F-FDOPA: A Multiple-Target Molecule J. Nucl. Med., December 1, 2009; 50(12): 1915 - 1918. [Abstract] [Full Text] [PDF]

				K. E. Oberg Is It Time to Widen the Use of Somatostatin Analogs in Neuroendocrine Tumors? J. Clin. Oncol., October 1, 2009; 27(28): 4635 - 4636. [Full Text] [PDF]

				H. u. Rehman Carcinoid syndrome Can. Med. Assoc. J., June 23, 2009; 180(13): 1329 - 1329. [Full Text] [PDF]

				E. Bajetta, V. Guadalupi, and G. Procopio Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors J. Clin. Oncol., January 10, 2009; 27(2): 319 - 320. [Full Text] [PDF]

				J. C. Yao In Reply: J. Clin. Oncol., December 20, 2008; 26(36): 6013 - 6015. [Full Text] [PDF]

				H. Scherubl Tumor Biology and Prognosis of Gastrointestinal Carcinoids J. Clin. Oncol., December 20, 2008; 26(36): 6012 - 6013. [Full Text] [PDF]

				S. N. Pinchot, K. Holen, R. S. Sippel, and H. Chen Carcinoid Tumors Oncologist, December 1, 2008; 13(12): 1255 - 1269. [Abstract] [Full Text] [PDF]